China's InnoCare, Eli Lilly Sign Collaboration Deal Worth Up To $3.35B
READ HERE
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
READ HERE
(Updates with details on licensing deal) Sept 24 (Reuters) — Chinese drugmaker InnoCare Pharma said on Thursday it had entered into a research collaboration and licensing agreement with Eli Lilly worth up to about $3.35 billion. Here are some more details: InnoCare would receive up to $100 million in upfront and near-t
Chinese drugmaker InnoCare Pharma SSE:688428 said on Thursday it entered into a research collaboration and license agreement with Eli Lilly NYSE:LLY that could be worth up to about $3.35 billion.